Table 3. Girls in which active fertility preservation intervention was pursued.
| Fertility preservation in HR group | |
|---|---|
| n = 16 | |
| Age at preservation (years) Median (range) | 4.6 (2.5–17.5) |
| Malignancy type | |
| Hematological * | 4 |
| Solid ** | 12 |
| Neuro-oncology | 0 |
| Type of preservation | |
| OTC-o (complete ovariectomy) | 13 |
| OTC-p (partial ovariectomy) | 0 |
| Oocyte cryopreservation (OC) | 1 |
| OC + OTC (complete ovariectomy) *** | 1 |
| Ovariopexy (OP) + OTC (complete ovariectomy) | 1 |
HR: high risk; OTC = Ovarian Tissue Cryopreservation.
* The hematologic malignancies included 1 patient with Acute Lymphoblastic Leukemia–HR protocol, 1 Acute Lymphoblastic Leukemia stem cell transplantation (SCT), 1 Acute Myeloid Leukemia SCT and 1 Myelodysplastic syndrome SCT.
** The solid tumors included 5 patients with neuroblastoma, 1 ovarian carcinoma, 3 Ewing sarcomas, 2 soft tissue sarcoma and 1 bilateral metastasized Wilms tumor receiving stem cell transplantation.
*** This high risk patient initially had the time to delay treatment for oocyte harvest. However due to the limited number of harvested oocytes and no time to perform another cycle, it was decided to additionally perform OTC.